

Gastroesophageal reflux disease – clinical practice guidelines

Grzegorz Wallner, Michał Solecki, Wiesław Tarnowski, Tadeusz Wróblewski, Edward Stanowski, Andrzej Budzyński, Maciej Michalik

Videosurgery and other miniinvasive techniques 2009; 4 (Suppl 1): S16–S24

Introduction

Guidelines for diagnosis and treatment of gastroesophageal reflux disease (GERD) were published by the American College of Gastroenterology (ACG) in 1995 and updated in 1999. Two years later another document was printed, signed by the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). This document defined indications for surgical treatment of GERD. Until now, there have been no clear criteria delineated by indigenous authors, especially in the specialty of gastroenterological surgery. Existent guidelines by the Polish Gastroenterological Society from 2005 do not fully cover surgical treatment issues.

Already in 1919 A. L. Soresi had written: “The possibility of gastroesophageal reflux disease remains an object of interest of both the gastroenterologist and the surgeon; however, when the diagnosis is established, the patient belongs to the surgeon”. This discordance in surgeons’ and gastroenterologists’ attitude to GERD demands new guidelines.

Gastroesophageal reflux disease definition

A new definition of GERD was established in the last decade. Jamieson and Duranceau’s definition presumed both physiological and pathological reflux – the latter called reflux disease, with or without morphological changes in oesophageal mucosa (Figure 1). In 2006 at the Montreal conference an evidence-based definition of GERD was established.

The global consensus on GERD definition aimed at simplification of the diagnostic and therapeutic process, scientific cooperation, and giving a chance for comparative studies for the benefit of patients, doctors, national health organizations and world insurance companies.

Finally GERD was defined as: “a chronic condition in which gastric content is regurgitated into the oesophagus and causes bothersome symptoms and/or complications” (Figure 2).

Diagnosis of reflux disease

After analysis of the literature and available meta-analyses of numerous clinical trials, the following rules in assessment of each patient with suspected GERD seem justified:




Figure 1. Classification of reflux disease according to Jamieson and Duranceau. Jamieson, Duranceau eds. Gastroesophageal reflux. Saunders 1988

Address for correspondence

Prof. Tadeusz Wróblewski, Department of General, Transplant and Liver Surgery, Warsaw Medical University, Banacha 1a, 02-097 Warsaw, e-mail: redakcja@wideochirurgia.pl




Figure 2. Reflux disease classification. The overall definition of GERD, and its constituent syndromes (Montreal classification). Am J Gastroenterol 2006; 101: 1900-1920

- 1) taking of detailed medical history,
- 2) physical examination,
- 3) additional diagnostic tests.

After detailed anamnesis, a further diagnostic and therapeutic plan can be devised. It can be simplified into a few points:

- 1) reflux disease as a cause of subjective discomfort,
- 2) cause of reflux disease in a specific patient,
- 3) consequences of pathological gastroesophageal reflux,
- 4) identification of patients at risk of complications typical for GERD,
- 5) identification of patients at risk of respiratory complications in the course of GERD,
- 6) risk factors affecting final result of treatment,
- 7) identification and qualification of patients for optimal (conservative or surgical) treatment modality.

Diagnostic guideline I: empirical therapy

- Initiation of treatment with proton pump inhibitor (PPI) at therapeutic dose.
- If symptoms are still present, further diagnostic steps should be done.

When typical symptoms of reflux disease are present (heartburn, regurgitation or both), often immediately after a large, fatty meal, and no risk

of disease complications or Barrett's oesophagus is suspected, pharmacological treatment can be attempted. A positive response with resolution of symptoms can be confirmative of such symptom origin. Combination of symptoms with endoscopic findings is highly specific for GERD (97%). Endoscopy should be recommended prior to empirical therapy only when disease complications are suspected or when both patient and doctor believe it ought to be done. Further studies should be considered if there is no response to empirical therapy.

Likelihood of GERD complications is higher when alarm symptoms (dysphagia, no effect of empirical therapy) are present.

Diagnostic guideline II: endoscopic examination

Endoscopic examination – necessary:

- diagnostic endoscopy with biopsies for histology whenever inflammatory changes are present;
- determination of the stage of the disease according to one of the classifications:
 - Savary-Miller,
 - Los Angeles,
 - MUSE;
- whenever a diagnosis of Barrett's oesophagus is made, the patient is referred to the National

Barrett's Oesophagus Registry; treatment of Barrett's oesophagus is another issue.

Endoscopy is a technology which allows for thorough examination of the oesophagus and identification of patients with GERD or Barrett's oesophagus. To confirm Barrett's oesophagus, biopsy or brush cytology is a must. This test provides assessment of the magnitude of inflammatory changes in mucosal lesions. When substantial inflammation is present and Barrett's epithelium is suspected, biopsies should be done after initial pharmacological treatment to make sure severe inflammation will not be taken for dysplasia on microscopic evaluation.

Broad spectrum of macroscopic changes in reflux disease is an indication for application of classifications and grading systems of disease progression. This simplifies assessment when the patient changes the centre and allows the course of the disease to be followed. Los Angeles classification is most often recommended in oesophagitis. The next most popular one is the Savary-Miller scale in original or modified version (Table I). MUSE classification is less common. So-called alarming symptoms (body weight reduction, GI bleeding, dysphagia), substantial symptom intensity and ineffectiveness of pharmacological therapy are particular indications for endoscopy. For assessment of metaplasia, Prague C&M classification is applied most often. To properly assess metaplasia, certain conditions must be met:

- skill of endoscopic diagnosis of metaplasia,
- ability to identify squamocolumnar junction (Z line) on endoscopy,
- ability to identify high pressure zone (diaphragmatic impression/hhe) on endoscopy,
- endoscopic definition of C (circumferential) area and M (maximum) protrusion of glandular epithelium into the oesophagus, for instance C2, M5.

However, biopsy remains the basis for microscopic verification.

Diagnostic guideline III: radiological studies

Radiological examination – indicated – with double contrast:

- assessment of the size and type of hiatal diaphragmatic hernia,
- initial judgement of oesophageal contractility (limited availability of oesophageal manometry in Poland),
- shortened oesophagus diagnosis – qualification for Collis gastroplasty.

Double contrast examination in its active phase provides valuable information when endoscopy cannot be done. It allows one to assess morphology of the oesophagus, strictures, and the size of large diaphragmatic hernias. It is also a valuable indication for a surgeon planning surgical treatment in the future. Reduction of the hernia in upright position gives a better chance for a tension-free procedure with no need for

Table I. Classifications of oesophagitis: Los Angeles, Savary-Miller and modified Savary-Miller

| Los Angeles | Savary-Miller | Modified Savary-Miller |
|---|--|--|
| A: at least one mucosa lesion < 5 mm long | I: one or more non-confluent mucosal lesions with erythema or exudate or superficial erosion | I: single erosive or exudative lesion, oval or linear, taking only one longitudinal fold |
| B: at least one mucosa lesion > 5 mm long, not affecting whole area between two neighbouring oesophageal mucosal folds | II: erosive or exudative mucosal lesions confluent without covering the entire circumference of the oesophagus | II: noncircular multiple erosions or exudative lesions taking more than one longitudinal fold, with or without confluence |
| C: at least one lesion of mucosa affecting whole area between two or more oesophageal mucosal folds, and less than 75% of oesophagus circumference | III: erosive and exudative lesions cover the whole oesophageal mucus membrane circumferentially and lead to inflammatory infiltration of the wall without stricture | III: circular erosive or exudative lesion |
| D: lesion of mucosa affecting at least 75% of circumference of the oesophagus | IV: appearance of chronic mucosal lesions (ulcer, fibrosis of the wall, stricture, short oesophagus, scarring with columnar epithelium) | IV: chronic lesions: ulcer(s), stricture(s), or short oesophagus, isolated or associated with lesions of grades I, II, or III |
| | | V: islands, finger-like forms or circumferential distribution of Barrett's epithelium isolated or associated with lesions of grades I to IV |

Collins gastroplasty when shortening of the oesophagus is present. Spontaneous contrast regurgitation in upright position is a pathognomonic sign.

Diagnostic guideline IV: pH-metry/multi-channel gastroesophageal impedance with pH monitoring

pH-metry/multi-channel intraluminal gastroesophageal impedance and pH monitoring is indicated in:

- unsure diagnosis and qualification for surgery,
- presence of clinical symptoms of reflux disease without endoscopic lesions,
- need for diagnosis of non-acidic or mixed type reflux,
- presence of extra-oesophageal symptoms,
- control of conservative or operative treatment.

To confirm a chain of cause-and-effect relationship of inflammatory changes in the oesophagus, studies monitoring reflux of gastric content into the oesophagus are indicated, especially when surgery is planned. Many patients with documented acidic gastric content regurgitation do not present with oesophagitis. On the other hand, there are patients with significant lesions or pronounced symptoms without any proof of acidic regurgitation. Adequately treated patients with persistent symptoms fall into the latter group. These patients finally are candidates for multi-channel intraluminal impedance and pH monitoring. This test allows for physical determination of the number of reflux episodes per day and assessment of regurgitated gastric content acidity. This test also affords control of treatment results and can be performed during therapy with PPI or histamine H2 receptor inhibitors.

Diagnostic guideline V: oesophageal manometry

Oesophageal manometry – test recommended in dysphagia, when aforementioned studies have been completed:

- assessment of motor activity of the oesophagus and lower oesophageal sphincter (LES),
- confirmation or exclusion of primary oesophageal motor activity changes,
- diagnosis of achalasia, diffuse oesophageal spasm (DES) or nutcracker oesophagus.

Allows for precise pH-metric sensor placement (5 cm above upper margin of lower oesophageal sphincter), documents normal or aberrant peristalsis

of the oesophagus and function of oesophageal sphincters. Propulsive function of the lower part of the oesophagus, length of its abdominal part and resting pressure of the lower oesophageal sphincter are all important information to a surgeon. Only these basic parameters give a chance for planning anti-reflux surgery. At present, high resolution manometry with intraluminal oesophageal impedance measurement is becoming more and more popular in pre-operative patient workup.

Gastroesophageal reflux disease pharmacotherapy

Detailed guidelines of pharmacotherapy were prepared and presented by the Working Group of the Polish Society of Gastroenterology (2005). A basis for any treatment is patients' will to cooperate. In many patients with GERD a decrease in magnitude of symptoms can be achieved with change of diet and lifestyle with small doses of anti-secretory agents. At the moment, PPI are recommended in two dosing schemes.

In the first regimen, therapy is begun with a single dose (10-20 mg) administered 20 min before breakfast. When there is no improvement, the single dose is doubled (20-40 mg), and when the problem persists, twice-daily dosage is introduced up to 80 mg per day in two fractionated doses. Administration of H2-inhibitor monotherapy is not recommended, as their efficacy is lower than PPI. In reasonable cases an additional night dose can be administered, reducing so-called nocturnal acidic regurgitation.

In the second regimen therapy is begun with high doses of PPI, which are reduced later to a dosage which allows for control of symptoms in a particular patient. It should be stressed that treatment ought to be tailored to each individual patient. Such regimens are described as step up and step down strategies. If surgical treatment is considered, and a patient has pronounced inflammatory lesions, pharmacotherapy is recommended as a first, safer choice with subsequent anti-reflux surgery.

Prokinetic agents, as aetiopathogenetically most reasonable, are not recommended either in GERD monotherapy or in combination with hyposecretory treatment. Commencing intensive treatment with high-dose PPI in patients with symptoms from the respiratory system potentially resulting from unconfirmed GERD should not be practised.

Surgical treatment

Indications for surgery concern only patients with well-documented reflux disease who:

- 1) did not improve in spite of intensive pharmacological therapy,
- 2) choose surgical treatment despite adequate pharmacological treatment, are young, have to constantly adhere to medical therapy even for the rest of their lives, which involves high expenses, or whose lifestyle excludes regular treatment,
- 3) develop reflux disease complications (Barrett's oesophagus, high grade oesophagitis),
- 4) have accompanying large hiatal hernia with complications such as bleeding or dysphagia,
- 5) have atypical symptoms (asthma, hoarse, chest pain, choking).

Operative treatment should not be considered only as an efficient alternative to pharmacotherapy, but should rather be seen as a method aimed at determining correction of the mechanical cause of reflux disease, with a satisfactory result achieved in 85-93% of patients. Guidelines for patient qualification for anti-reflux surgery, accepted by the American Society of Gastroenterology, are as follows:

- no effect of pharmacotherapy,
- patients requiring increasing dosage of therapy, with disease progression,
- no effect of maintenance therapy – development of complications (shortening of oesophagus, ulceration, motor impairment) despite pharmacotherapy,
- young patients, requiring long-term aggressive therapy,
- patient non-adherence, costs, fear of drug side effects,
- refusal of chronic pharmacotherapy,
- patients with stage 3-4 reflux oesophagitis with high risk of complications – mostly with non-acidic and mixed reflux,
- patients with low grade dysplasia, with efficient LES,
- patients with large sliding hiatus hernia resistant to pharmacological treatment,
- complicated reflux disease – strictures, ulcerations, Barrett's oesophagus,
- pulmonary complications – aspiration, repeated pneumonias, chronic laryngitis, and other extra-oesophageal symptoms.

When planning surgical treatment in reflux disease so-called absolute indications for operative treatment should also be considered:

- perforation of:
 - Barrett's ulcer,
 - gastric peptic ulcer within the thorax,
 - iatrogenic (instrumental);
- uncontrolled bleeding from GI tract:
 - Barrett's ulcer,
 - peptic ulcer of the stomach within the thorax;
- signs of bowel obstruction:
 - organic stricture type,
 - advanced peptic stricture;
- necrosis of the stomach:
 - organic stricture with signs of strangulation;
- aspiration to respiratory system resistant to therapy:
 - recurrent laryngitis or tracheitis,
 - recurrent bronchitis;
- signs of malignancy:
 - confirmed or suspected malignancy in Barrett's oesophagus.

Special attention must be paid to patients with Barrett's oesophagus due to the risk of adenocarcinoma development. Resection of the oesophagus ought to be considered if the patient presents with extensive lesions and high-grade dysplasia.

The goal of the surgical anti-reflux procedure is to stop gastric content regurgitation. Its superiority over pharmacotherapy has been proven in numerous controlled clinical studies. Anti-reflux surgery efficiently corrects a mechanically deficient existing valve and prevents temporary loss of sphincter function occurring at distension of the stomach. Years-long studies have shown such correction to alleviate heartburn and regurgitation symptoms, cure oesophagitis, inhibit disease progression and be effective 10 years after surgery. The efficacy of surgical treatment depends on the experience of the surgeon and adequate preoperative patient assessment.

Goals of surgical treatment are as follows:

- 1) obtain appropriate length of the abdominal part of the oesophagus from its mobilization to secure tension-free fundoplication, which would stay below the diaphragm,
- 2) prepare and mobilize the gastric fundus widely enough to make sure that the formed cuff would not rotate in the longitudinal axis and decrease the tension of fundoplication,
- 3) reduce diaphragmatic hiatus opening.

The gold standard for treatment of reflux disease is now laparoscopic fundoplication. This method has brought about a significant reduction of hospitalization and patient convalescence time. Full Nissen's or Nissen-Rosetti's fundoplication is recommended in patients with normal oesophageal motor function. In patients with significant dysfunction, non-complete posterior Toupet's fundoplication should be considered. Descriptions of anti-reflux procedures are widely available in the literature and identical for both open and laparoscopic access. Choice of technique depends on the surgeon's preferences and practicality; numerous modifications of the mentioned methods can be seen.

In some cases, such as coexistent chest pathology, or grade 3 or 4 incarcerated diaphragmatic hiatus hernia, the procedure can be completed through thoracotomy, yet it is not recommended access.

When short oesophagus is found or when there is significant tension after reducing reconstructed cardia into the abdominal cavity, the Collis procedure with fundoplication ought to be done.

Endoscopic treatment

As a method with expected high efficacy and low complication rate, endoscopic treatment is gaining increasing popularity and is a subject of meticulous assessment of clinical efficiency. At the moment, only two methods are accepted by FDA: Stretta and EsophyX™. Recommendations for biopolymers have been withdrawn due to the substantial complication rate. EsophyX™ is a minimally invasive method of reflux disease treatment, and has recently been approved in the European Union for endoscopic fundoplication. The Stretta method uses radio-frequency energy on the LES and the subcardial area. This results in an increase of LES tension and muscular layer hypertrophy and decreases the number of transient sphincter relaxations. It is the only method with efficacy confirmed with randomized studies. Radiofrequency is also used for Barrett's epithelium ablation with Halo 360 and Halo 90 apparatus. More traditional measures, such as endoscopic mucosectomy, argon or laser ablation, have been used for a much longer time. Any procedure of Barrett's epithelium removal ought to be supplemented with surgical or endoscopic fundoplication.

Summary

Reflux disease is a serious problem of not only medical, but also economic significance. The costs of long-term pharmacological treatment are tremendous. Surgical treatment for the majority of these patients seems justified. Such therapy ought to be undertaken in a centre with the volume exceeding 50 anti-reflux procedures per year. The procedure performed by an experienced surgeon gives a chance for remission of symptoms for over 5 years in more than 90% of patients. Application of laparoscopic techniques has made this method of treatment much more attractive.

References

1. Vakil N, van Zanten SV, Kahrilas P, et al.; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. *Am J Gastroenterol* 2006; 101: 1900-1920.
2. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al.; American Gastroenterological Association. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. *Gastroenterology* 2008; 135: 1383-1391.
3. Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. *Gastroenterology* 2008; 135: 1392-1413.
4. Jamieson GG, Duranceau A. *Gastroesophageal Reflux*. Philadelphia, Saunders 1988.
5. Bremner CG, Peracchia A, DeMeester T. Modern approach to benign esophageal disease. *Quality Medical Publ* 1995; 3: 57.
6. Sharma P, Dent J, Armstrong D, et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C&M criteria. *Gastroenterology* 2006; 131: 1392-1399.
7. Paris Workshop on Columnar Metaplasia in the Esophagus and the Esophagogastric Junction, Paris, France, December 11-12 2004. *Endoscopy* 2005; 37: 879-920.
8. Choroba refluksowa przełyku. Misiuna P (red). Wyd. Fundacja Polski Przegląd Chirurgiczny, Warszawa 1999; 61-79.
9. Nowak A, Marek T, Rydzewska G. Wytyczne Polskiego Towarzystwa Gastroenterologii: choroba refluksowa przełyku. *Gastroenterol Pol* 2005; 12: 313-319.
10. DeMeester TR, Peters JH, Bremner CG, Chandrasoma P. Biology of gastroesophageal reflux disease: pathophysiology relating to medical and surgical treatment. *Annu Rev Med* 1999; 50: 469-490.
11. Lundell L. Therapy of gastroesophageal reflux: evidence-based approach to antireflux surgery. *Dig Dis* 2007; 25: 188-196.
12. Hinder RA. Surgical therapy of GERD: selection of procedures, short- and long-term results. *J Clin Gastroenterol* 2000; 30 (3 Supl.): S48-50.

13. Minjarez RC, Jobe BA. Surgical therapy for GERD. Dostępne na: www.nature.com/gimo 2006.
14. Ginsberg RJ, Pearson FG. Indications for surgical referral for hiatal hernia and GERD: the surgeon's perspective. Churchill Livingstone 2002.
15. Kauer WK, Peters JH, DeMeester TR, et al. A tailored approach to antireflux surgery. *J Thorac Cardiovasc Surg* 1995; 110: 141-146.
16. Dallemagne B, Weerts JM, Jhaes C, et al. Laparoscopic Nissen fundoplication; preliminary report. *Surg Laparosc Endosc* 1991; 1: 138-143.
17. DeMeester TR, Bonavina L, Albertucci M. Nissen fundoplication for gastroesophageal reflux disease. Evaluation of primary repair in 100 consecutive patients. *Ann Surg* 1986; 204: 9-20.
18. Hinder RA, Filipi CJ. The technique of laparoscopic Nissen fundoplication. *Surg Laparosc Endosc* 1992; 2: 265-272.
19. Peters JH, DeMeester TR, Crookes P, et al. The treatment of gastroesophageal reflux disease with laparoscopic Nissen fundoplication: Prospective evaluation of 100 patients with "typical" symptoms. *Ann Surg* 1998; 228: 40-50.
20. Bonatti H, Hinder RA. Technical considerations in laparoscopic fundoplication. How I do it. *J Gastrointest Surg* 2007; 11: 923-928.
21. Hinder RA, Perdakis G, Klinger PJ, DeVault KR. The surgical option for gastroesophageal reflux disease. *Am J Med* 1997; 103: 144S-148S.
22. Lieberman DA. Medical therapy for chronic reflux esophagitis: long-term follow-up. *Arch Intern Med* 1987; 147: 1717-1720.
23. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. *Am J Med* 2003; 114: 1-5.
24. Tytgat GN, McColl K, Tack J, et al. New algorithm for the treatment of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2008; 27: 249-256.
25. Kirby CN, Piterman L, Nelson MR, Dent J. Gastro-oesophageal reflux disease. Impact of guidelines on GP management. *Aust Fam Physician* 2008; 37: 73-77.
26. Rice S, Watson DI, Lally CJ, et al. Laparoscopic anterior 180 degrees partial fundoplication: five-year results and beyond. *Arch Surg* 2006; 141: 271-275.
27. Wijnhoven BP, Watson DI, Devitt PG, et al. Laparoscopic Nissen fundoplication with anterior versus posterior hiatal repair: long-term results of a randomized trial. *Am J Surg* 2008; 195: 61-65.
28. Guérin E, Bétroune K, Closset J, et al. Nissen versus Toupet fundoplication: results of a randomized and multicenter trial. *Surg Endosc* 2007; 21: 1985-1900.
29. Sgromo B, Irvine LA, Cuschieri A, Shimi SM. Long-term comparative outcome between laparoscopic total Nissen and Toupet fundoplication: symptomatic relief, patient satisfaction and quality of life. *Surg Endosc* 2008; 22: 1048-1053.
30. Herbella FA, Tedesco P, Nipomnick I, et al. Effect of partial and total laparoscopic fundoplication on esophageal body motility. *Surg Endosc* 2007; 21: 285-288.
31. Engström C, Lönnroth H, Mardani J, Lundell L. An anterior or posterior approach to partial fundoplication? Long-term results of randomized trial. *World J Surg* 2007; 31: 1221-1225.
32. Chandrasoma PT, DeMeester TR. GERD: reflux to esophageal adenocarcinoma. Elsevier Inc. 2006.
33. Vakil N. Review role: The role of surgery in gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2007; 25: 1365-1372.
34. Mahon D, Rhodes M, Decadt B, et al. Randomized clinical trial of laparoscopic Nissen fundoplication compared with proton-pump inhibitors for treatment of chronic gastro-oesophageal reflux. *Br J Surg* 2005; 92: 695-699.
35. Mehta S, Bennett J, Mahon D, Rhodes M. Prospective trial of laparoscopic Nissen fundoplication versus proton pump inhibitor therapy for gastroesophageal reflux disease: 7 year follow-up. *J Gastrointest Surg* 2006; 10: 1312-1317.
36. Ortiz A, Martinez de Haro LF, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett's esophagus: long-term results of a prospective study. *Br J Surg* 1996; 83: 274-278.
37. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. *JAMA* 2001; 285: 2331-2338.
38. Chang EY, Morris CD, Seltman AK, et al. The effect of anti-reflux surgery on esophageal carcinogenesis in patients with Barrett esophagus: a systematic review. *Ann Surg* 2007; 246: 11-21.
39. Lagergren J, Viklund P. Is esophageal adenocarcinoma occurring late after antireflux surgery due to persistent postoperative reflux? *World J Surg* 2007; 31: 465-469.
40. Lundell L, Miettinen P, Myrvold HE, et al.; Nordic GORD Study Group. Seven-year follow-up of a randomized clinical trial comparing proton-pump inhibition with surgical therapy for reflux oesophagitis. *Br J Surg* 2007; 94: 198-203.
41. Lundell L, Attwood S, Ell C, et al.; LOTUS trial collaborators. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. *Gut* 2008; 57: 1207-1213.
42. Zaninotto G, Portale G, Costantini M, et al. Objective follow-up after laparoscopic repair of large type III hiatal hernia. Assessment of safety and durability. *World J Surg* 2007; 31: 2177-2183.
43. Turkcapar A, Kepenekci I, Mahmoud H, Tuzuner A. Laparoscopic fundoplication with prosthetic hiatal closure. *World J Surg* 2007; 31: 2169-2176.
44. Granderath FA, Schweiger UM, Pointner R. Laparoscopic anti-reflux surgery: tailoring the hiatal closure to the size of hiatal surch area. *Surg Endosc* 2007; 21: 542-548.
45. Salminen PT, Hiekkanen HI, Rantala AP, Ovaska JT. Comparison of long-term outcome of laparoscopic and conventional nissen fundoplication: a prospective randomized study with an 11-year follow-up. *Ann Surg* 2007; 246: 201-206.
46. Varela JE, Hinojosa MW, Nguyen NT. Laparoscopic improves perioperative outcomes of antireflux surgery at US academic centers. *Am J Surg* 2008; 196: 989-993.
47. Lord RV, DeMeester SR, Peters JH, et al. Hiatal hernia, lower esophageal sphincter incompetence and effectiveness of Nissen fundoplication in the spectrum of gastroesophageal reflux disease. *J Gastrointest Surg* 2009; 13: 602-610.
48. Mardani J, Lundell L, Lönnroth H, et al. Ten-year results of a randomized clinical trial of laparoscopic total fundoplication with or without division of the short gastric vessels. *Br J Surg* 2009; 96: 61-65.

49. DeVault KR, Castell DO; American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. *Am J Gastroenterol* 2005; 100: 190-200.
50. Hinder RA, Libbey JS, Gorecki P, Bammer T. Antireflux surgery. Indications, preoperative evaluation, and outcome. *Gastroenterol Clin North Am* 1999; 28: 987-1005.
51. Hinder RA. Gastroesophageal reflux disease: Surgical outcomes. Scientific Sessions Handouts, AGA 2002, San Francisco.
52. Sontag SJ, Sonnenberg A, Schnell TG, et al. The long-term natural history of gastroesophageal reflux disease. *J Clin Gastroenterol* 2006; 40: 398-404.
53. Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorical disease. *Am J Gastroenterol* 2006; 101: 2457-2462.
54. Stoltey J, Reebea H, Ullah N, et al. Does Barrett's oesophagus develop over time in patients with chronic gastro-oesophageal reflux disease? *Aliment Pharmacol Ther* 2007; 25: 83-91.
55. Kawanishi M. Will symptomatic gastroesophageal reflux disease develop into reflux esophagitis? *J Gastroenterol* 2006; 41: 440-443.
56. Skinner DB, Belsey RH. Surgical management of esophageal reflux and hernia hiatus. Long-term results with 1030 patients. *J Thorac Cardiovasc Surg* 1967; 53: 33-54.
57. Skinner DB, Belsey RH. Surgical management of esophageal reflux and hernia hiatus. Long-term results with 1030 patients. *J Thorac Cardiovasc Surg* 1967; 53: 33.
58. Falk GW, Fennerty MB, Rothstein RL. AGA Institute medical position statement on the use of endoscopic therapy for gastroesophageal reflux disease. *Gastroenterology* 2006; 131: 1313-1314.
59. Pearl JP, Marks JM. Endoluminal therapies for gastroesophageal reflux disease: are they dead? *Surg Endosc* 2007; 21: 1-4.
60. Špičák J. Treatment of gastroesophageal reflux disease: Endoscopic aspects. *Dig Dis* 2007; 25: 183-187.
61. Triadafilopoulos G. Endotherapy and surgery of GERD. *J Clin Gastroenterol* 2007; 41 Supl. S87-S96.
62. Pleskow D, Rothstein R, Kozarek R, et al. Endoscopic full-thickness plication for the treatment of GERD: long-term multicenter results. *Surg Endosc* 2007; 21: 439-444.
63. Schwartz MP, Wellink H, Gooszen HG, et al. Endoscopic gastroplication for the treatment of gastro-oesophageal reflux disease: a randomised, sham-controlled trial. *Gut* 2007; 56: 20-28.
64. Omura N, Kashiwagi H, Yano F, et al. Prediction of recurrence after laparoscopic fundoplication for erosive reflux esophagitis based on anatomy-function-pathology (AFP) classification. *Surg Endosc* 2007; 21: 427-430.
65. Boeckstaens GE. Review article: the pathophysiology of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 2007; 26: 149-160.
66. Tobey NA. How does the esophageal epithelium maintain its integrity? *Digestion* 1995; 56 Supl. 1: 45-50.
67. Fein M, Ritter MP, DeMeester TR, et al. Role of lower esophageal sphincter and hiatal hernia in the pathogenesis of gastroesophageal reflux disease. *J Gastrointest Surg* 1999; 3: 405-410.
68. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. *J Clin Invest* 1980; 65: 256-267.
69. Dent J, Dodds WJ, Friedman RH, et al. Mechanism of gastroesophageal reflux in recumbent asymptomatic human subjects. *J Clin Invest* 1980; 65: 256-267.
70. Trudgill NJ, Riley SA. Transient lower esophageal sphincter relaxations are no more frequent in patients with gastroesophageal reflux disease than in asymptomatic volunteers. *Am J Gastroenterol* 2001; 96: 2569-2574.
71. Sifrim D, Holloway R. Transient lower esophageal sphincter relaxations: how many or how harmful? *Am J Gastroenterol* 2001; 96: 2529-2532.
72. Jones MP, Sloan SS, Rabine JC, et al. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal disease. *Am J Gastroenterol* 2001; 96: 1711-1717.
73. van Herwaarden MA, Samsom M, Smout AJ. The role of hiatus hernia in gastro-oesophageal reflux disease. *Eur J Gastroenterol Hepatol* 2004; 16: 831-835.
74. van Herwaarden MA, Samsom M, Smout AJ. The role of hiatus hernia in gastro-oesophageal reflux disease. *Eur J Gastroenterol Hepatol* 2004; 16: 831-835.
75. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. *Am J Gastroenterol* 1999; 94: 2054-2059.
76. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. *Am J Gastroenterol* 1999; 94: 2054-2059.
77. Sarosiek J, McCallum RW. What role do salivary inorganic components play in health and disease of the esophageal mucosa? *Digestion* 1995; 56 (Supl. 1): 24-31.
78. Bass BL, Trad KS, Harmon JW, Hakki FZ. Capsaicin-sensitive nerves mediate esophageal mucosal protection. *Surgery* 1991; 110: 419-26.
79. Tutuian R, Vela MF, Shay SS, Castell DO. Multichannel intraluminal impedance in esophageal function testing and gastroesophageal reflux monitoring. *J Clin Gastro* 2003; 37: 206-215.
80. Sifrim D, Castell D, Dent J, et al. Gastroesophageal reflux monitoring: reviews and consensus report on detections and definitions of acid, nonacid, and gas reflux. *Gut* 2004; 53: 1024-31.
81. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. *Am J Gastroenterol* 2006; 101: 1900-1920.
82. Wallner G, Solecki M, Huk J, et al. Jednoczasowy pomiar impedancji i pH w przełyku – nowa technika diagnostyczna choroby refluksowej przełyku. Doświadczenia własne. *PPCh* 2007; 79: 884-892.
83. GERD – Reflux to esophageal carcinoma. Chandrasoma PT, DeMeester TR (red.). Elsevier, Amsterdam 2006.
84. Dreuw B, Fass J, Büchlin P, et al. Combined pH measurement and multiple impedance variation assessments – validation of a new technique for detection of non-acid reflux in the esophagus. *Langenbecks Arch Chir Suppl Kongressbd* 1998; 115: 1143-5.
85. Kawamura O, Aslam M, Rittmann T, et al. Physical and pH properties of gastroesophagopharyngeal refluxate: a 24-hour simultaneous ambulatory impedance and pH monitoring study. *Am J Gastroenterology* 2004; 99: 1000-1010.

86. Balaji NS, Blom D, DeMeester TR, Peters JH. Redefining gastroesophageal reflux (GER). *Surg Endosc* 2003; 17: 1380-1385.
87. Shay S, Sifrim D, Tutuian R, et al. Multichannel intraluminal impedance in the evaluation of patients with persistent GERD symptoms despite proton pump inhibitors: a multicenter study. *Gastroenterology* 2003; 124: A-537.
88. Canon CL, Morgan DE, Einstein DM, et al. Surgical approach to gastroesophageal reflux disease: what the radiologist needs to know. *Radiographics* 2005; 25: 1485-1499.
89. Joh T, Miwa H, Higuchi K, et al.; ARS Research Group. Validity of endoscopic classification of nonerosive reflux disease. *J Gastroenterol* 2007; 42: 444-449.
90. Dostępne na: <http://www.lapsurgery.com/sagegerd.htm>.
91. Jian R, Hassani Z, El Kebir S, Barthélemy P. Management of gastro-esophageal reflux disease in primary care. Results from an observational study of 2474 patients (AO). *Gastroenterol Clin Biol* 2007; 31: 72-77.
92. Wallner G, Abramowicz K, Misiuna P. Choroba refluksowa przełyku. *Biblioteka PPCh* 1999; 4: 61-79.
93. Vaezi MF, Richter JE. Synergism of acid and duodenogastro-esophageal reflux in complicated Barrett's esophagus. *Surgery* 1995; 117: 699-704.
94. Sharma P, McQuaid K, Dent J, et al.; AGA Chicago Workshop. A critical review of the diagnosis and management of the Barrett's esophagus. *Gastroenterology* 2004; 127: 310-330.
95. Jones R, Galmiche JP. Review: What do we mean by GERD? – definition and diagnosis. *Aliment Pharmacol Ther* 2005; 22 (Supl. 1): 2-10.
96. Hirano I, Richter JE; Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. *Gastroenterology* 2007; 102: 668-685.
97. Ginsberg RJ, Pearson FG. Indications for Surgical Referral for Hiatal Hernia and GERD: The Surgeon's Perspective. *Churchill Livingstone* 2002.
98. DeMeester TR. What are the operative indications in reflux? W: *The esophageal mucosa*. Giuliani R, Tytgat GN, DeMeester TR, Galmiche JP (red.). Elsevier Science B.V. Amsterdam 1994; 524-527.
99. Hinder RA. Therapy of GERD: Selection of procedures, short- and long-term results. *J Clin Gastroenterol* 2000; 30.
100. Catarci M, et al. Evidence-based appraisal of antireflux fundoplication. *Ann Surg* 2004; 239: 325-337.
101. Neuhauser B, Bonatti H, Hinder RA. Treatment strategies for gastroesophageal reflux disease. *Chirurg* 2003; 74: 617-624.
102. Wallner G, Solecki M. Zasady rozpoznawania i leczenia choroby refluksowej przełyku. *Chir po Dypl* 2009; 4 (w druku).
103. Wróblewski T, Skalski M, Ziarkiewicz-Wróblewska B, et al. Nowa technika chirurgicznego leczenia refluksu żołądkowo-przełykowego. *Videosurgery and other miniinvasive techniques* 2007; 2: 139-144.
104. Migaczewski M, Budzyński A, Rembiasz K, Choruz R. Ocena jakości życia osób z chorobą refluksową przełyku leczonych laparoskopową fundoplikacją sposobem Nissena. *Videosurgery and other miniinvasive techniques* 2008; 3: 119-125.
105. Wróblewski T, Grodzicki M, Ziarkiewicz-Wróblewska B, et al. Aspekty techniczne i wyniki laparoskopowej fundoplikacji sposobem Toupet w leczeniu zaawansowanej postaci refluksu żołądkowo-przełykowego (GERD). *Videosurgery and other miniinvasive techniques* 2006; 1: 6-9.
106. Wróblewski T, Skalski M, Ziarkiewicz-Wróblewska B, et al. Postępy w leczeniu chirurgicznym choroby refluksowej. *Videosurgery and other miniinvasive techniques* 2006; 1: 121-124.
107. Grubnik VV, Malinovsky AV, Grubnik AV. Relationship between subjective and objective data in achalasia patients after laparoscopic Heller-Dor procedure. *Videosurgery and other miniinvasive techniques* 2006; 1: 137-141.